The complexity of psoriatic disease, with its interplay

The gap

Evidence profile

Sourced from the stated challenges and recommendations and future work of the source papers, classified as general, spanning 2 journals.

Supporting evidence — 3 representative gaps

• The immunometabolic tipping point: forecasting the systemic shift from psoriasis to psoriatic arthritis (2026) · Frontiers in Immunology · doi

  The complexity of psoriatic disease, with its interplay of genetic, immunological, and metabolic factors, poses a significant challenge. The need for longitudinal studies to determine whether expansion of CD8+CCR10+ T cells precedes the clinical onset of psoriatic arthritis is a challenge. The development of robust predictive models that can identify patients at high risk of psoriatic arthritis development is a challenge.

  generalstated challenges
  Keywords: complexity psoriatic disease interplay genetic immunological metabolic factors
• Using causal machine learning and real world data to improve dose response decision making for secukinumab in psoriatic arthritis (2026) · Scientific Reports · doi

  2021. Nat. Rev. Rheumatol. 18, 465-479 (2022). 11. Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329-1339 (2015). 12. McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386, 1137-1146 (2015). 13. Nash, P. et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res. Ther. 20, 47 (2018). 14. Kivitz, A. J. et al. Efficacy and safety of subcutaneous secukinumab 150 mg with or without in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol. Ther. 6, 393-407 (2019). regimen loading 15. Mease, P. et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann. Rheum. Dis. 77, 890-897 (2018). 16. EMA.

  generalrecommendationsevidence 5/5
  Keywords: arthritis secukinumab psoriatic future patients rheumatol mease interleukin randomised double blind placebo controlled phase trial
• Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease (2026) · Frontiers in Immunology · doi

  In conclusion, psoriasis and Crohn’s disease are linked by partial immune convergence rather than by complete disease identity. Epidemiological, clinical, genetic, transcriptomic, spatial, and therapeutic evidence supports overlap at the level of selected upstream inflammatory programs, especially TNF-a signaling and IL-23-centered type 17 immunity. However, these shared programs are interpreted differently by skin and gut tissue ecologies, including barrier architecture, resident immune niches, microbial exposure, trafficking programs, and repair demands. This explains why similar upstream pathways can produce distinct tissue outcomes and divergent therapeutic responses. Therapeutically, TNF inhibition, IL-12/23 blockade, and selective IL-23 inhibition currently provide the strongest rationale for dual- organ compatibility in selected patients, whereas IL-17 blockade and paradoxical psoriasiform reactions illustrate the limits of directly translating shared immune pathways into interchangeable treatment targets. Therefore, coexisting cutaneous psoriasis and Crohn’s disease should not automatically be managed as a single shared phenotype. Treatment decisions should be guided by dominant organ burden, synchronized or discordant disease activity, prior biologic exposure, psoriatic arthritis status, and objective inflammatory assessment. Future studies should identify which patients with psoriasis and Crohn’s disease actually share a cross-organ inflammatory phenotype, rather than assuming that pathway overlap applies to all coexisting cases. This will require validated biomarkers, tissue-based profiling, longitudinal monitoring of skin and intestinal activity, and prospective studies specifically designed for patients with coexisting disease. This evidence is needed before shared immune biology can be used reliably to guide treatment in individual patients.

  generalfuture workevidence 5/5
  Keywords: disease immune shared patients psoriasis crohn ammatory programs tissue organ treatment coexisting rather therapeutic evidence

Questions about this gap